Paradoxical palmoplantar pustulosis induced by secukinumab and brodalumab: a report of three cases

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Puig L. Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. Curr Probl Dermatol 2018; 53: 49–63.

    Article  Google Scholar 

  2. 2.

    Dogra S, Bishnoi A, Narang T, Handa S. Secukinumab-induced paradoxical pustular psoriasis. Clin Exp Dermatol 2019; 44: 72–3.

    CAS  Article  Google Scholar 

  3. 3.

    Nakao M, Asano Y, Kamata M, Yoshizaki A, Sato S. Successful treatment of palmoplantar pustular psoriasis with brodalumab. Eur J Dermatol 2018; 28: 538–9.

    Article  Google Scholar 

  4. 4.

    Takahashi H, Sato K, Takagi A, Iizuka H. Brodalumab-induced palmar pustular eruption and joint swelling accompanied by muscle pains in two cases of psoriasis. J Dermatol 2018; 45: e325–6.

    Article  Google Scholar 

  5. 5.

    Wilsmann-Theis D, Jacobi A, Frambach A, et al. Palmoplantar pustulosis — a cross-sectional analysis in Germany. Dermatol Online J 2017; 23: 4.

    Google Scholar 

  6. 6.

    Mössner R, Thaci D, Mohr J, et al. Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases. Arch Dermatol Res 2008; 300: 101–5.

    Article  Google Scholar 

  7. 7.

    Bae JM, Lee HH, Lee BI, et al. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther 2018; 48: 196–205.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Rotraut Mössner or Andreas Pinter.

Additional information

Disclosure

Funding source: none. Conflicts of interest: RM has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials by the following companies: Abbott/Abbvie, Allmirall, Biogen IDEC GmbH, Böhringer-Ingelheim, Celgene, Essex Pharma GmbH, Janssen-Cilag GmbH, Leo Pharma GmbH, Lilly, Merck Serono GmbH, MSD SHARP & DOHME GmbH, Novartis Pharma GmbH, Pfizer GmbH and UCB. AP has been an advisor and/or received speakers’ honoraria and/or received grants and/or participated in clinical trials by the following companies: AbbVie, Almirall-Hermal, Amgen, Biogen Idec, Boehringer-Ingelheim, Celgene, GSK, Eli-Lilly, Galderma, Hexal, Janssen, LEO-Pharma, MC2, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Schering-Plough und UCB Pharma.

Supplementary material

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mössner, R., Pinter, A. Paradoxical palmoplantar pustulosis induced by secukinumab and brodalumab: a report of three cases. Eur J Dermatol 30, 177–178 (2020). https://doi.org/10.1684/ejd.2020.3702

Download citation